Case studies

We’re dedicated to realizing your vision through a passionately progressive approach designed just for you. By taking this approach to every project, our world-class team with deep scientific and technical expertise help to unlock the full potential of your product.

Explore our full range of case studies below to discover how we’ve helped innovators just like you.

Biosimilars: A comparability study

Biosimilars: A comparability study

A customer approached Enzene Biosciences to complete comparability testing, focusing on the comparison of the physiochemical and biological properties of a biosimilar monoclonal antibody (mAb) drug product to the reference medicinal product (RMP). Find out how we helped them achieve success.

Harnessing a continuous perfusion process for improved productivity

Harnessing a continuous perfusion process for improved productivity

A client approached Enzene, struggling to run a fed-batch beyond 10 days, which only produced a very low titer of 600 to 700 mg when cultured. Find out how we helped them achieve success.

Implementing enhanced lyophilized cycling for a stable drug product

Implementing enhanced lyophilized cycling for a stable drug product

A customer approached Enzene Biosciences for the development of a lyophilization cycle to produce a stable drug product that remained safe and efficacious. Find out how we helped them achieve therapeutic success.

Leveraging continuous manufacturing for efficient mAb production

Leveraging continuous manufacturing for efficient mAb production

Enzene Biosciences was approached by a customer working on a monoclonal antibody (mAb) for the treatment of osteoporosis in women who have an increased risk of fractures, but production suffered from low productivity. Find out how we helped them achieve therapeutic success.

Optimizing manufacturing of a complex bispecific antibody

Optimizing manufacturing of a complex bispecific antibody

An emerging biotech approached Enzene Biosciences with a novel Fully Human Albumin Binding (FHAB) protein, which suffered from low titers, poor viability after 10 days of growth, proteolytic clipping, limited operational pH range, and host cell protein (HCP) problems. Find out how we helped them achieve success.

Overcoming challenges for the production of a novel engineered mAb

Overcoming challenges for the production of a novel engineered mAb

Enzene Biosciences were opproached to help overcome an upstream batch bottleneck for their human-engineered mAb product.

Join the revolution

Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.